Description: Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc.
Home Page: regenbiopharmainc.com
4700 Spring Street
La Mesa,
CA
91942
United States
Phone:
619 722 5505
Officers
| Name | Title |
|---|---|
| Dr. David Raymond Koos | Chairman, CEO, Pres, Sec. & Treasurer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 89.7276 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 1 |